TrialThe Journal of infectious diseases2023

Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.

Babafemi O Taiwo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.